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902Objectives: Ubiquitin carboxyl-terminal esterase-L1 (UCHL1) is a protein highly selectively expressed in neu-
rons and has been linked to neurodegenerative disease in humans. We hypothesize that UCHL1 would be an
effective serum biomarker for brain injury as tested in canine models of hypothermic circulatory arrest
(HCA) and cardiopulmonary bypass (CPB).
Methods:Dogs were exposed to CPB (n¼ 14), 1 hour of HCA (1h-HCA; n¼ 11), or 2 hours of HCA (2h-HCA;
n¼ 20). Cerebrospinal fluid and serumwere collected at baseline, 8 hours, and 24 hours after treatment. UCHL1
levels were measured using a sandwich enzyme-linked immunosorbent assay. Neurologic function and histopa-
thology were scored at 24 hours, and UCHL1 immunoreactivity was examined at 8 hours.
Results: Baseline UCHL1 protein levels in cerebrospinal fluid and serum were similar for all groups. In serum,
UCHL1 levels were elevated at 8 hours after treatment for 2h-HCA subjects compared with baseline values
(P<.01) and also compared with CPB dogs at 8 hours (P<.01). A serumUCHL1 level above 3.9 ng/(mg total pro-
tein) at 8 hours had the best discriminatory power for predicting functional disability. In cerebrospinal fluid,UCHL1
was elevated in all groups at 8 hours after treatment compared with baseline (P<.01). However, UCHL1 levels in
cerebrospinal fluid remained elevated at 24 hours only in 2h-HCA subjects (P<.01). Functional and histopathologic
scores were closely correlated (Pearson coefficient, 0.66;P<.01) andwere significantlyworse in 2h-HCA animals.
Conclusions: This is the first report associating elevated serum UCHL1 with brain injury. The novel neuronal
biomarker UCHL1 is increased in serum 8 hours after severe neurologic insult in 2h-HCA animals compared
with CPB animals. These results support the potential for use in cardiac surgery patients and form the basis
for clinical correlation in humans. (J Thorac Cardiovasc Surg 2011;142:902-10)Supplemental material is available online.DivisionofCardiac Surgery,aDepartments ofNeurology,bNeuroscience,c and
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The Journal of Thoracic and Cardiovascular SurgDespite advances in operative and anesthetic techniques,
neurologic injury remains a devastating problem after car-
diac surgery, with stroke rates between 1% and 6%.1,2
Furthermore, delirium after coronary artery bypass
increases the risk of long-term mortality,3 and cognitive
dysfunction is present in nearly one quarter of patients at
1 month.4 Patients with neurologic injury have increased
hospital length of stay, cost, and need for inpatient rehabil-
itation.2 Although the risk of stroke remains relatively low,
with nearly 300,000 cardiac surgical procedures performed
annually in the United States,5 neurologic injury is a signif-
icant burden to patients, their families, and the health care
system.
Nearly 35 years have elapsed since hypothermic circula-
tory arrest (HCA) was first introduced for cerebral protec-
tion during aortic arch reconstructions.6 Yet, end organ
damage remains a significant problem in the setting of
HCA, and there are no currently proven strategies to prevent
brain injury.7,8 In the evolution of the surgical approach to
conditions that require temporary cerebral blood flow
exclusion, some centers have studied selective antegrade
perfusion or retrograde cerebral perfusion.9,10 However,ery c October 2011
Abbreviations and Acronyms
CNS ¼ central nervous system
CPB ¼ cardiopulmonary bypass
CSF ¼ cerebrospinal fluid
ELISA ¼ enzyme-linked immunosorbent assay
HCA ¼ hypothermic circulatory arrest
UCHL1 ¼ ubiquitin carboxyl-terminal esterase-
L1
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SHCA remains an established and viable strategy for
complex aortic arch repairs and congenital cardiac lesions
and is still widely used at many centers.8,11,12
Experimental evidence has implicated post-HCA glutamate
excitotoxicity as an important mediator of this injury.13 Dif-
ferential gene regulation has been detected in dogs undergo-
ing HCA as compared with cardiopulmonary bypass (CPB)
only, further elucidating the mechanisms in HCA-related
brain injury.14
Brain injury is often diagnosed several hours to days after
surgery; detecting neurologic injury early after the initial in-
sult can enable clinicians to diagnose and implement treat-
ments to reverse or mitigate the damage. Thus, the
development of readily obtainable biomarkers that correlate
with early brain injury harbors much promise for improving
neurology related morbidity after cardiac surgery. Several
biomarkers for brain injury have been widely studied,
such as neuron-specific enolase, glial protein S-100 beta),
and myelin basic protein; however, none has been defini-
tively correlated with clinical outcomes, and studies relat-
ing these proteins to pathophysiologic parameters are
lacking.15 Our laboratory detected spectrin breakdown
products as biomarkers for central nervous system (CNS)
injury, although these findings were confined to the cerebro-
spinal fluid (CSF).16
Because of abundant expression in neurons, ubiquitin
carboxyl-terminal esterase-L1 (UCHL1) (first recognized
as neuron-specific gene product 9.5)17 has garnered enthu-
siasm as a potential CNS biomarker. UCHL1 accounts for
nearly 5% of total soluble brain protein, is involved in
ubiquitination pathways, and has been linked with neuro-
degenerative disorders such as Parkinson disease in hu-
mans.18 Recent evidence supports the detectable presence
of UCHL1 in CSF in animal and human studies of sub-
arachnoid hemorrhage and ischemic and traumatic brain
injury.19-22 To date, there is only 1 study examining
UCHL1 elevations after cardiac surgery, but those results
were limited to CSF samples.23 Given the mounting
evidence for UCHL1 as a biomarker for neuronal injury,
we tested the hypothesis that UCHL1 is an effective serum
biomarker for brain injury in a canine model of CPB and
HCA.The Journal of Thoracic and CaMETHODS
Animals
We used our clinically relevant canine model of HCA and
CPB.13,14,16,24,25 Six- to 12-month-old, 30-kg male class A dogs were
used (Marshal Bioresources, North Rose, NY). The Johns Hopkins Animal
Care and Use Committee approved the experimental protocols, which com-
plied with the ‘‘Guide for the Care and Use of Laboratory Animals’’ (1996,
US National Institutes of Health).Experimental Design
Dogs were randomly exposed to 2 hours of HCA (2h-HCA; n ¼ 20), 1
hour of HCA (1h-HCA; n ¼ 11), or CPB alone (n ¼ 14) and survived to
either 8 hours (2h-HCA, n ¼ 10; 1h-HCA, n ¼ 5; and CPB, n ¼ 8) or 24
hours (2h-HCA, n ¼ 10; 1h-HCA, n ¼ 6; and CPB, n ¼ 6) after treatment.
CSF and serum samples were collected at baseline (before the surgical in-
cision but after induction of anesthesia), at 8 hours, and 24 hours. For both
baseline and subsequent CSF collection, under sedation and in a routine
sterile fashion, the spinal canal is entered with a 22-gauge needle through
the cisterna magnum (at the base of the skull posteriorly). Samples are im-
mediately frozen in a80C freezer. Blood samples are obtained through
previously placed peripheral intravenous catheters, cold centrifuged to col-
lect serum, and frozen at80C. At the conclusion of the experiment, all
subjects were humanely killed by exsanguination, and brains were har-
vested for analysis.
Surgical HCA procedure. Anesthesia was induced with metho-
hexital sodium 9 mg/kg. Animals were endotracheally intubated and main-
tained on inhaled isoflurane (0.5%-2%), 100% oxygen, and intravenous
fentanyl (150-200 mg/dose). Tympanic membrane, esophageal, and rectal
probes monitored temperatures throughout the experiment. A left femoral
artery cannula was placed for arterial blood gas and hemodynamic
monitoring.
Standard CPB circuits with a 40-mm arterial filter (Sorin Group, Arvada,
Colo) were used in all experiments. Intravenous heparin (300U/kg) was ad-
ministered and the right femoral artery cannulated (12F-14F), advancing
the cannula into the abdominal aorta. Two separate venous cannulas
(18F-20F) were advanced to the right atrium via the right femoral and ex-
ternal jugular veins. Vessels were cannulated by an open cutdown
technique. Closed-chest CPB was initiated using pump flows of 60 to
80 mL $ kg1 $ min1 to maintain mean arterial pressure of 60 to 80 mm
Hg, and activated clotting times were maintained greater than 500 seconds.
For animals in the 1h-HCAor 2h-HCAgroups, the pumpwas stoppedwhen
tympanic temperatures reached 18C (approximately 30 minutes).
Animals underwent 1h-HCA or 2h-HCA with alpha-stat regulation of
arterial blood gases (pH, 7.3-7.4; arterial partial pressure of oxygen>
300 mm Hg; and carbon dioxide, 30-40 mm Hg). Once HCA finished,
CPB was resumed and rewarming commenced (5C temperature gradi-
ent every 15 minutes to a core temperature of 37C for 2 hours). Intra-
venous phenylephrine was used when necessary to maintain mean
arterial pressure greater than 75 mm Hg. External defibrillation was per-
formed when temperatures were 32C. At 37C, animals were separated
from CPB, decannulated, and reversed with protamine (3 mg/kg
intravenous).
Animals recovered from anesthesia while intubated, with frequent mon-
itoring of vital signs, arterial blood gases, and urine output. Once hemody-
namically and clinically stable, they were extubated and transferred to their
crate for recovery. Analgesics were administered per protocol after the
procedure.
CPB only. After induction and cannulation, animals underwent 2 hours
of CPB without HCA. Animals were cooled to 32C, and the heart contin-
ued to beat during this operation. Animals were allowed to recover from
anesthesia as described above.
Neurologic assessment. The University of Pittsburgh Canine Neu-
rological Score was independently determined at 24 hours by 2 nonblindedrdiovascular Surgery c Volume 142, Number 4 903
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level of consciousness, respiration, cranial nerve function, reflexes, behav-
ior, and motor and sensory function. Animals had normal neurologic func-
tion before experimentation. No additional sedation was given within 12
hours of neurologic assessment.
Humane death and tissue procurement. Animals were se-
dated, intubated, and anesthetized. A sternotomy was performed, 300
units/kg of heparin given, and the ascending aorta cannulated (22F).
Cold perfusion via the aortic cannula flushed the brain with 12 L of saline
solution (4C) at 60 mmHg. The right atrial appendage was transected and
venous return suctioned into a reservoir. Brains were harvested by a wide
craniectomy.
Tissue preparation and UCHL1 immunohistochemistry.
Brains were immersion-fixed for 1 week in 4% paraformaldehyde, cut into
2-mm coronal blocks, embedded in paraffin, and sectioned at 6 mm. For im-
munohistochemistry, endogenous peroxidasewas quenched (3% hydrogen
peroxide in methanol, 10 minutes, room temperature), slides were blocked
(phosphate-buffered saline with 5% normal goat serum, 0.2% Triton X-
100 [Union Carbide Corporation, Danbury, Conn], and 0.2% gelatin, 60
minutes, RT) and incubated in rabbit anti-UCHL1 (Novus Biologicals
NB100-65827 [Novus Biologicals, Littleton, Colo], 1:1600 in phosphate-
buffered saline with 1.5% normal goat serum, 0.2% Triton X-100, 0.2%
gelatin, and 1 mL/mL sodium azide, 48 hours, 4C). The primary antibody
was visualized using the avidin–biotin–peroxidase complex method (ABC-
Elite; Vector Laboratories, Inc, Burlingame, Calif).Histologic Analysis
Hematoxylin and eosin staining was performed for blinded histologic
evaluation by a single neuropathologist (J.C.T.). Eleven distinct regions
of the canine brain were evaluated for the presence of apoptosis and necro-
sis. These regions include midfrontal cortex, superior parietal cortex, basal
ganglia, hippocampus (dentate gyrus and CA regions), entorhinal cortex,
amygdala, cerebellum (molecular layer, Purkinje layer, and granule layer),
and brainstem. A semiquantitative scale was used to assess the degree of
necrosis and apoptosis in each region. These scores were summed to obtain
the neuronal cell death score, ranging from a minimum of 0 (no damage) to
a maximum of 99 (extreme neuronal damage).
ELISA Analysis
UCHL1 levels in CSF and serum were measured using a UCHL1 sand-
wich enzyme-linked immunosorbent assay (ELISA)modified from a proto-
col previously reported.20,21 Mouse monoclonal antihuman UCHL1
antibody and rabbit polyclonal antihuman UCHL1 antibody were made
in-house against recombinant human UCHL1 full-length protein and par-
tial protein, respectively. Both were affinity purified and specificity was
confirmed by immunoblotting. Reactionwells were coated with capture an-
tibody (purified mouse monoclonal antihuman UCHL1) in 0.05-mol/L so-
dium bicarbonate, pH 9.6, and incubated overnight at 4C. Plates were then
washed with blocking buffer (Tris buffer salinewith 0.02% Tween-20 [vol-
ume/volume]) and further incubated for 30 minutes at ambient temperature
with gentle shaking. Antigen standard (UCHL1 standard curve, 0, 0.06-15
ng/mL), unknown samples (5 mL of CSF; 20 mL of serum), or assay internal
control samples were incubated overnight with detection antibody (rabbit
polyclonal antihuman UCHL1, 100 mL total volume). The capture
antibody-coated plate was then incubated with detection antibody sample
mixture for 1.5 hours at room temperature and washed using an automatic
plate washer (each well rinsed with 350 mL Tris/Tween-20 wash buffer).
The plate was then incubated with antirabbit–immunoglobulin G–horse-
radish peroxidase (Amersham Biosciences, Buckinghamshire, United
Kingdom) at room temperature for 1 hour and developed with Ultra-
TMBELISA substrate (Pierce No. 34028; Thermo Scientific Pierce Protein
Research Products, Rockford, Ill) for 10 minutes. The plate was read at 450
nm with a Molecular Devices Spectramax 190 spectrophotometer904 The Journal of Thoracic and Cardiovascular Surg(Molecular Devices, Inc, Sunnyvale, Calif). The intra-assay coefficient
of variance equaled 2.1% to 7.9% whereas the interassay coefficient of
variance equaled 0.9% to 10.6 % within the assay dynamic range. The
limit of detection was 0.030 ng/mL; samples with undetectable levels
were assigned 50% of the limit of detection (ie, 0.015 ng/mL). If samples
yielded a signal above the quantification range, samples were diluted and
reassayed. For all serum samples, concentrations were normalized against
total serum protein concentration for the same sample (ng/mg protein).
Genomic Analysis
Canine microarray analysis was performed in a blinded fashion at the
Johns Hopkins Deep Sequencing and Microarray Core Facility. Detailed
methods of this protocol have been described previously.14 Gene expres-
sion profiles in samples from ventral anterior hippocampus were com-
pared between 2h-HCA, 1h-HCA, CPB, and untreated normal dogs
(each treatment group was compared with normal controls). Exploratory
data analysis was performed on normalized data with a false discovery
rate less than 0.10 considered significantly regulated.27 Entrez Gene
IDs for human orthologs were assigned to evaluate gene function, and In-
genuity Pathways Analysis software (Ingenuity Systems, Inc, http://www.
ingenuity.com, Redwood City, Calif) was used to identify proteins that in-
teract directly with UCHL1 or are part of canonical pathways that include
UCHL1. For UCHL1-related genes that were significantly regulated in
one or more treatment groups, fold change versus normal was determined
in all groups.
Statistical Analysis
Neurologic scores are presented as mean  standard deviation. One-
way analysis of variance compared neurologic and histologic scores
among groups. For all subjects, the paired comparisons t test examined
differences in levels of UCHL1 from baseline to 8 hours after treatment.
For animals surviving 24 hours, repeated-measures analysis of variance
was used to account for the repeated serum samples from within the
same canine subject over time. Post hoc pairwise comparisons were con-
ducted using the Tukey-Kramer method. Correlations between functional
and histopathologic scores were assessed using linear regression and the
Pearson correlation coefficient. Threshold values for UCHL1 levels that
predict severe functional impairment (neurologic score>100) were deter-
mined using unadjusted logistic regression and receiver operating charac-
teristic curves (area under the curve > 0.7 considered significant).
Analysis was performed using STATA software (version 9.2; StataCorp-
LP, College Station, Tex).
RESULTS
Subjects
Twenty dogs underwent 2h-HCA, 11 had 1h-HCA, and
14 had CPB. Roughly half of the dogs in each group (2h-
HCA, n ¼ 10; 1h-HCA, n ¼ 5; and CPB, n ¼ 8) were hu-
manely killed at 8 hours and the other half at 24 hours.
Neurologic Scores
Using the neurologic scoring system (0-480), higher
scores indicate worse neurologic function. Scores at 24
hours were significantly different among groups, with lower
scores observed in groups subjected to milder insult
(Figure 1). For 2h-HCA animals, the mean neurologic score
was 185  28. In 1h-HCA animals, the mean score was 40
 50. Two 1h-HCA dogs were effectively normal
(scores< 20); in contrast, no 2h-HCA dog had a score
less than 130: all were severely impaired. CPB animalsery c October 2011
FIGURE 1. Average neurologic scores (based on 2 independent ob-
servers) for animals 24 hours after 2h-HCA, 1h-HCA, or CPB, using the
University of Pittsburgh Canine Neurological Score (0-480, with higher
scores corresponding with greater functional neurologic impairment). *In-
dicates P<.05 by Tukey-Kramer method post hoc pairwise comparisons.
ANOVA, Analysis of variance; HCA, hypothermic circulatory arrest; CPB,
cardiopulmonary bypass; h, hours.
Arnaoutakis et al Evolving Technology/Basic Sciencedemonstrated negligible change in neurologic function
(mean score, 16  16).
Histopathology Scores
Dogs exposed to 2h-HCA had the highest levels of cellu-
lar injury on histologic examination (mean neuronal cell
death score, 9.6  5.5; Table 1). This level was different
when compared with 1h-HCA and CPB groups. Most brain
regions showed minimal neuronal death, but at 24 hours in
the 2h-HCA group the hippocampus was severely affected
(up to 75% apoptotic neurons in the dentate gyrus). Linear
regression analysis showed a strong correlation between
histopathologic scores and University of Pittsburgh Func-
tional Assessment scores (Figure 2).
Immunohistochemistry Results
UCHL1 staining in the hippocampus was less in 2h-HCA
animals than in 1h-HCA and CPB subjects. In the dentate
gyrus, there was moderate expression of UCHL1 in the
CPB group but almost complete loss of protein expressionTABLE 1. Average histologic scores for neuronal cell death (total and by b
Brain region Potential score 2h-
Composite score of all brain regions examined 99 9
Notable regions
Cortex 18 1
Basal ganglia 9 1
Hippocampus 18 3
Cerebellum 27 0
HCA, Hypothermic circulatory arrest; CPB, cardiopulmonary bypass. Eleven distinct brain
basal ganglia, hippocampus (dentate gyrus and CA region), entorhinal cortex, amygdala, ce
corresponds to 1-way analysis of variance. ySignificantly different from reference (CPB) on
1h-HCA on post-hoc pairwise using Tukey-Kramer test. x2h-HCA subjects demonstrate e
The Journal of Thoracic and Cain the 2h-HCA group. In the CA3 region, there was a change
from high expression in the CPB group to moderate expres-
sion in pyramidal neurons after 2h-HCA. However, there
was near-complete loss of UCHL1 in the mossy fiber layer
after 2h-HCA, where axon terminals from the depleted den-
tate granule neurons are located (Figure 3).
ELISA Results
Serum. In 2h-HCA animals, serum UCHL1 levels were in-
creased from baseline 8 hours after treatment (3.2 0.3 ng/
mg protein to 9.3  2.0 ng/mg protein; P ¼ .01) but were
similar to baseline by 24 hours (Figure 4, A). In 1h-HCA
and CPB animals, serum levels of UCHL1 were not ele-
vated at either time point. Comparison of the 3 groups re-
vealed that 2h-HCA animals had significantly elevated
UCHL1 in serum at 8 hours compared with CPB
(P ¼ .01), but by 24 hours there were no longer any detect-
able differences among the groups. Correlation of serum
UCHL1 levels for the 3 groups against University of Pitts-
burgh Functional Assessment scores revealed that 3.9 ng/
mg total protein appeared the most sensitive break point
for predicting functional impairment in an unadjusted logis-
tic regression analysis (area under receiver operating char-
acteristic curve, 0.9; P ¼ .02) (Figure 4, B).
CSF. In 2h-HCA animals, UCHL1 protein in CSF was
significantly increased from baseline 8 hours after HCA
(11.7  6.0 ng/mL to 144.5  21.7 ng/mL; P< .01) and
remained elevated 24 hours after HCA (P< .01). In 1h-
HCA and CPB animals, UCHL1 levels were elevated at
8 hours compared with baseline (1h-HCA, 5.4  2.4
ng/mL to 56.218.6 ng/mL; P ¼ .01; CPB, 12.4  6.1
ng/mL to 68.1  21.0 ng/mL; P ¼ .02) but returned to
baseline levels at 24 hours. Comparison among the 3
groups at 8 and 24 hours revealed that 2h-HCA animals
had elevated levels of UCHL1 compared with 1h-HCA
and CPB animals at both time points (Figure E1, A).
CSF levels of UCHL1 for the 3 groups were correlated
with University of Pittsburgh Functional Assessment
scores. The most sensitive break point for predicting func-
tional impairment in an unadjusted logistic regression
analysis was 61 ng/mL (receiver operating characteristic
curve area, 0.77; P ¼ .09) (Figure E1, B).rain region)
HCA (n ¼ 10) 1h-HCA (n ¼ 6) CPB (n ¼ 6) P value*
.6 (5.5)y,z 4.1 (2.2) 0.7 (1.3) <.01
.3 (1.4)y,z 0.5 (0.7) 0 (0) .02
.0 (0.5)y,z 0.6 (0.6) 0.1 (0.3) <.01
.2 (0.9)y,z 1.3 (0.9)y 0.1 (0.3) <.01
.9 (0.9)x 0.9 (0.8) 0.1 (0.4) .14
regions examined included the following: midfrontal cortex, superior parietal cortex,
rebellum (molecular layer, Purkinje layer, and granule layer), and brainstem. *P value
post hoc pairwise comparisons using Tukey-Kramer test. zSignificantly different from
xcessive hemorrhage on histologic analysis.
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FIGURE 2. Linear regression analysis depicting correlation between his-
topathology scores and University of Pittsburgh Functional Assessment
Scores. Strength of correlation was determined using linear regression
analysis with the Pearson coefficient and R2 value. HCA, Hypothermic cir-
culatory arrest; CPB, cardiopulmonary bypass.
FIGURE 3. UCHL1 immunoreactivity (left panel) and corresponding Nissl-sta
1h-HCA (C, D), and 2h-HCA (E, F). UCHL1, Ubiquitin carboxyl-terminal este
pass; SO, stratum oriens; P, pyramidal neurons; MF, mossy fiber layer; SR, stra
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In 2h-HCA animals, 3 genes were significantly regulated
at 8 hours, and 8 genes were significantly regulated at 24
hours. In the 1h-HCA group, 1 gene was significantly regu-
lated at 8 hours and none at 24 hours. No genes were signif-
icantly regulated in the CPB group. Among the regulated
genes, 3 messenger RNAs for proteins that directly interact
with UCHL1 and 2 messenger RNAs for proteins in the Par-
kin pathway were significantly downregulated, but 6 mes-
senger RNAs for proteasome subunits were significantly
upregulated. Detailed information regarding regulated
genes is shown in Table E1.DISCUSSION
The promising field of proteomics has facilitated the de-
velopment of new biomarkers specific for organ injury.
The advantages of neuron-specific biomarkers are three-
fold: Earlier detection of brain injury may (1) allow
for therapeutic, pharmacologic, and hemodynamicined sections (right panel) in CA3 region of hippocampus for CPB (A, B),
rase-L1; HCA, hypothermic circulatory arrest; CPB, cardiopulmonary by-
tum radiatum.
ery c October 2011
FIGURE 4. Line graph (A) showing serum levels of UCHL1 by treatment groups across 3 time points. Scatter plots (B) for serumUCHL1 levels correlated
with functional assessment score. Break point denoted by dashed line indicates highest sensitivity for predicting outcome of interest (Neuro Score>100) by
univariate logistic regression analysis. ANOVA, Analysis of variance; HCA, hypothermic circulatory arrest; CPB, cardiopulmonary bypass; UCHL1, ubiq-
uitin carboxyl-terminal esterase-L1.
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in future research. UCHL1 is a candidate serum biomarker
known to be abundant with high specificity in neurons.17,26
It has further been linked with several neurodegenerative
diseases in humans, including Parkinson disease.18 Dogs
undergoing prolonged HCA (2 hours) had significant in-
creases in serum UCHL1 protein at 8 hours compared
with baseline and compared with the CPB group at 8
hours. The 2h-HCA dogs also had greater neurologic im-
pairment and histologic damage. Immunohistochemistry
analysis elucidated plausible biologic mechanisms to sup-
port the ELISA results, and genomic analysis suggests
downregulation of proteins that bind to UCHL1 and possi-
ble compensatory upregulation of proteasomal subunits.
Taken collectively, these findings support the use of
UCHL1 as a serum biomarker specific for neurologic in-
jury after HCA.
Consistent with our earlier work, dogs subjected to 2h-
HCA sustained significantly greater histologic damage
(most pronounced in the hippocampus) compared with
those subjected to 1h-HCA and CPB only. Because our pur-
pose was to assess the utility of the UCHL1 biomarker as an
indicator of clinical brain injury, we used the University of
Pittsburgh Functional Assessment score (cutoff> 100) as
our dependent variable in unadjusted logistic regression
analysis. This scoring system is a validated instrument for
this purpose, and regression analysis confirmed a reliable
correlation between this measure of neurologic impairment
and histopathologic scores (Figure 2).26 This supports our
decision to use the functional assessment score as the out-
come measure; however, this outcome measure was deter-
mined only at 24 hours of survival.The Journal of Thoracic and CaThe immunohistochemistry results substantiate the ele-
vated levels of UCHL1 detected in the CSF and serum.
ICH staining revealed a progressive loss of neuronal
UCHL1 protein with increasing severity of treatment,
which is consistent with the progressive increase observed
in CSF. The brains of animals subjected to CPB had pre-
served UCHL1 immunoreactivity within intact neurons.
This staining was less intense for 1h-HCA dogs and greatly
diminished in the 2h-HCA group. Consistent with this find-
ing, 11 genes intimately related to UCHL1 were upregu-
lated or downregulated after 2h-HCA; in comparison,
only 1 gene was significantly regulated in 1h-HCA and
none after CPB only. This transcriptional profile across
the 3 treatment groups mirrors our earlier findings on tran-
scriptional regulation among a broad array of gene cate-
gories and supports the safety of CPB.14 In this study, we
elected to use Ingenuity Pathways Analysis to identify
genes related to UCHL1. This system is human-curated
and, therefore, only validated interactions and plausible
mechanistic pathways are considered.
We detected elevations of UCHL1 in the CSF at 8 hours
among all 3 study groups. However, serum elevations of
UCHL1 were observed only in the 2h-HCA group at 8
hours. So that sensitivity and specificity will be enhanced
in clinical use, a panel of biomarkers with different time
course profiles for release and degradation will be impor-
tant, akin to the use of serummarkers for myocardial infarc-
tion. Although the sandwich ELISA yields highly
quantitative results, we applied rigorous methods to stan-
dardize the serum concentrations by using the total protein
concentration for the respective sample. Thus, we believe
the serum results are robust and valid.rdiovascular Surgery c Volume 142, Number 4 907
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findings, demonstrating release of UCHL1 protein from in-
jured neurons in the 2h-HCA group. Although UCHL1 re-
lease is believed to be associated with neuronal injury/
death, we believe that the early presence of this biomarker
may aid in identification of threatened yet salvageable neu-
rons in adjacent regions of the brain (after intraoperative or
perioperative hypoperfusion or watershed infarctions).
Pharmacologic interventions, as well as aggressive treat-
ment of hypoxia and hypotension, may spare these threat-
ened neurons. Future clinical studies are needed to fully
assess the ability of this marker to influence such therapies.
PREVIOUS WORK
Our laboratory has previously reported the elevations of
spectrin breakdown products in the CSF after 1h-HCA.16
A novel contribution of the current study is the detection
of a novel biomarker specific for CNS injury in serum. Ad-
ditional studies have investigated the role of UCHL1 as
a biomarker in the setting of traumatic brain injury,
subarachnoid hemorrhage, and ischemia–reperfusion
injury.19-21,23 Papa and associates21 detected higher CSF
levels of UCHL1 in 44 human patients who had sustained
traumatic brain injury. That study examined additional
time points, with detailed characterization of the time
course of CSF UCHL1 protein levels; however, the mech-
anism of neurologic injury differs from HCA. Lewis and
colleagues19 reported 30 patients with elevations of CSF
UCHL1 after subarachnoid hemorrhage and observed
higher mortality rates among patients with the highest
levels of UCHL1. Siman and coworkers23 conducted the
only study to date conducted in cardiac surgery patients,
with all 19 patients undergoing thoracic aortic aneurysm
repair, 7 of whom required HCA. Among the 12 patients
not requiring HCA (aortic crossclamping only), patients
with acute neurologic complications had higher CSF
UCHL1 levels, suggesting UCHL1 release in response to
warm ischemia and reperfusion injury. This study did
not, however, examine serum levels of UCHL1. Our study
builds on these existing data by identifying serum eleva-
tions of UCHL1 associated with neurologic injury in the
setting of HCA.
LIMITATIONS
This study is limited with respect to the temporal pattern
of biomarker release into the CSF and serum. The current
data suggest that UCHL1 peaks in the serum 8 hours after
HCAand begins to lower by 24 hours. However, it is possible
that there is an earlier peak.We acknowledge this limitation;
however, we attempted to balance study feasibilitywith prior
experience regarding the temporal release of UCHL1 after
neurologic injury. Additional studies of groups having
shorter survival times are currently being conducted to ad-
dress this important issue. This study also does not provide908 The Journal of Thoracic and Cardiovascular Surgdata regarding long-term or late release of this biomarker;
such information can only be gleaned from longer survival
models, which pose additional logistical obstacles. There
are outliers within the data points, but these were not ex-
cluded to preserve the purity of the data set. Also, when
the relationship between functional impairment and serum
UCHL1 concentrations within individual treatment groups
is examined (Figure 4, B), there does not appear to be a pos-
itive correlation. We speculate that a larger sample size and
more sensitive functional assessment (as can be performed in
humans) would address these limitations.
We were unable to control for the effects of hypothermia
on UCHL1 release. Hypothermia maymediate pathways in-
volved in the release of UCHL1. However, given prior ex-
perience suggesting a protective effect of hypothermia on
neurologic function28 and the preponderance of evidence
suggesting that UCHL1 is released in response to neuro-
logic injury, it is unlikely that the serum presence of
UCHL1 observed in this study is due purely to hypothermia.
Furthermore, it would be difficult to achieve such an exper-
imental condition, inasmuch as all animals experience
spontaneous ventricular fibrillation when undergoing con-
trolled hypothermia.
From a logistical standpoint, if we were to have designed
a comparison control group that was progressively cooled
for 30 minutes to deep hypothermia and rewarmed after-
ward, our past experience suggests nearly all of these
dogs would have had a period of ventricular fibrillation.
The HCA groups are not subjected to a prolonged duration
of ventricular fibrillation because the pump is turned off
during the arrest phase. The groups would have been better
matched with respect to the incidence of fibrillation (and the
requirement of defibrillation); however, this hypothetical
control group would have been exposed to a longer period
of fibrillation.
Additionally, we acknowledge that a 2-hour period to in-
duce injury is quite severe and does not mirror clinical prac-
tice. However, the dogs used in this study were all young,
healthy animals without cerebrovascular disease or prior
stroke. In the interest of efficient use of animals and re-
sources, we chose to study an HCA duration that exceeded
clinical practice but would ensure histologic damage and
maximize the likelihood of detecting biomarker elevations
in the serum.
CONCLUSIONS
In summary, this is the first study to document serum el-
evation of UCHL1 after neurologic injury. The novel neuro-
nal biomarker UCHL1 is increased in serum 8 hours after
severe neurologic insult in 2h-HCA animals compared
with animals in the CPB group. These results support the
potential for practical use in patients undergoing cardiac
surgery and form the basis for clinical correlation in human
studies.ery c October 2011
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Dr J. William Gaynor (Philadelphia, Pa). I have 2 questions.
First, is this marker expressed in tissues other than the brain? We
have seen problems with some other markers such as S100 ex-
pressed in other tissues that can be injured. Second, what is the
developmental expression? Obviously, I am interested in the im-
mature brain. Is it constant throughout development or is it in-
volved in control of development? Is the differential expressed
in the developing brain?
Dr Arnaoutakis. Thank you for those questions. I will address
your second point first. The candidate biomarkers that we have
looked at have been developed in tandem with our collaborators
in Gainesville, Florida, who specialize in proteomics, and so far
as they know, developmentally, the expression of this protein is
consistent.
Your first question is an especially important one because there
is the issue of confounding if these biomarkers are expressed in tis-
sues of organs that are not of interest.
UCH has 3 isoforms: L1, L2, and L3. The L1 isoform, as best
we can tell, is very specific to neurons. L2 and L3 have been iden-
tified in tumors but I do not believe they are expressed in normal
tissue. We do believe that UCHL1 is very specific. UCHL1 ac-
counts for about 5% of total soluble brain protein, which may
seem low, but given the gamut of the variety of brain proteins ex-
pressed, it is actually a very high amount. So we actually have seen
in other models, together with Dr Wang, that this seems to be a re-
producible and very specific biomarker.
DrMichael E. Jessen (Dallas, Tex). I enjoyed your talk. This is
a very important area for research. My question about this partic-
ular marker is how pragmatic it really is. It seems to me that you
have to deliver a pretty severe insult to the animal before you startrdiovascular Surgery c Volume 142, Number 4 909
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as well. Does that detract from its clinical usefulness, whereas
what we really need is something that will be detected even
when subtle changes occur so that we would have the ability to
intervene?
Dr Arnaoutakis. That is a great point and I appreciate your
bringing that up. There are a couple of points to address in your
question. The animals that we have used in our model are young,
healthy, male dogs without any cerebrovascular disease or comor-
bidities. You are right that, to achieve damage, we have to subject
these animals to a rather profound insult. However, we do believe
that this has promise in humans who may have cerebrovascular
disease and comorbidities and would require a less severe insult
for this biomarker to be released. We think that these results sup-
port a follow-up study in humans in which we would evaluate the
serum.
The other point that you bring up is especially important in the
discussion of biomarkers. I know there are data both in the car-
diac surgery literature and in the critical care literature regarding
acute kidney injury biomarkers, for example, in which there are
actually profiles of biomarkers that enhance the sensitivity. We
have experience in our laboratory with biomarkers other than
UCHL1. Each has a limitation. Some are not as specific to the
brain as UCHL1 but are also expressed in higher levels with
less severe injury.
I think ultimately what we are looking for and what we would
aim to do with our human studies is not limit ourselves ahead of
time by only making preparations to study a single biomarker.
Rather, we would incorporate a panel so that we could increase
our sensitivity and not have to rely on any single biomarker to pre-
dict devastating neurologic injury, which is frequently manifest
clinically anyway.
Dr Jessen.How quickly can you get the results of an ELISA af-
ter you send the blood off so that you might have information on
which you would be able to intervene?910 The Journal of Thoracic and Cardiovascular SurgDr Arnaoutakis. Speaking to the logistics, at this point we are
collaborating with a laboratory in a different state. Having said
that, this laboratory has developed significant expertise with its
ELISA and its methods. Down the road, the intention is for this
to be used as a point of care test, so that it could actually be per-
formed either in the intensive care unit or in the critical laboratory,
making these results available in real time and allowing them to in-
form clinical decision making.
Dr Sunil P. Malhotra (New York, NY). Biomarkers of neuro-
logic injury are a very important area for cardiac surgery in gen-
eral. My question is this: You looked at 8 hours and 24 hours,
but I think it is important to evaluate the reversibility of brain in-
jury. Do you have any data on any long-term results, such as
a few days out, if the markers come down and if that correlates
with the canine score? Have you correlated this with any magnetic
resonance imaging or axial imaging of functional assessment of
brain injury?
Dr Arnaoutakis. Those are great points. The longest-term data
that we have is what I presented—24 hours. It is mainly for logis-
tical reasons through our animal care use committee and a canine
model. However, we actually have preparations for a longer-term
model to study these animals out to 1 week from their insult so that
we can glean better information regarding the time course profile
of these markers. From what we do have, it appears that the
UCHL1 is actually decreasing in the serum at least at 24 hours.
From the standpoint of damage, I know that the histologic char-
acteristics actually evolve over time such that at 8 hours, even after
2 hours of hypothermic circulatory arrest, there is not nearly as
much histologic damage as what we have seen in some of our
72-hour survival animals. The other interesting point related to
your question regarding longer term is that there may be bio-
markers that are expressed in the period of time 48 hours to even
1 week out from injury that may shed some light on longer-term
neurologic injury months down the road. That is an area that we
are investigating as well.ery c October 2011
FIGURE E1. Line graph (A) depicting CSF levels of UCHL1 by treatment groups across 3 time points. Scatter plots (B) for CSF UCHL1 concentration
correlated with functional assessment score. Break point denoted by dashed line indicates highest sensitivity for predicting outcome of interest (Neuro score
> 100) by univariate logistic regression analysis. ANOVA, Analysis of variance; HCA, hypothermic circulatory arrest; CPB, cardiopulmonary bypass;
UCHL1, ubiquitin carboxyl-terminal esterase-L1; CSF, cerebrospinal fluid.
TABLE E1. Numbers of significantly regulated genes at 8 and 24 hours after 2h-HCA, 1h-HCA, and CPB
Gene
Fold change vs normal group
Gene name
2h-HCA
8h Surv
2h-HCA
24h Surv
1h-HCA
8h Surv
1h-HCA
24h Surv
CPB
8h Surv
CPB
24h Surv
USP21 1.38 2.05 1.04 1.14 1.05 1.06 Ubiquitin specific peptidase 21
PSMB8 1.12 2.22 1.13 1.18 1.12 1.11 Proteasome (prosome, macropain) subunit, beta type, 8
(large multifunctional peptidase 7)
PSME2 1.17 1.69 1.02 1.19 1.10 1.07 Proteasome (prosome, macropain) activator subunit 2
(PA28 beta)
PSMB10 1.16 1.90 1.03 1.45 1.31 1.07 Proteasome (prosome, macropain) subunit, beta type, 10
PSMB9 1.16 1.58 1.57 1.19 1.52 1.16 Proteasome (prosome, macropain) subunit, beta type, 9
(large multifunctional peptidase 2)
PSMA6 1.07 1.27 1.02 1.13 1.06 1.08 Proteasome (prosome, macropain) subunit, alpha type, 6
SEPT5 1.24 1.46 1.21 1.02 1.04 1.02 Septin 5
PSMB3 1.16 1.27 1.05 1.23 1.10 1.13 Proteasome (prosome, macropain) subunit, beta type, 3
VHL 1.17 1.04 1.11 1.01 1.04 1.01 Von Hippel-Lindau tumor suppressor
SNCAIP 1.25 1.04 1.20 1.04 1.25 1.08 Synuclein, alpha interacting protein
MYCN 1.25 1.01 1.41 1.17 1.36 1.02 V-myc myelocytomatosis viral related oncogene,
neuroblastoma derived (avian)
Bold numbers indicate gene terms significantly regulated for each treatment group with a false discovery rate less than 0.1. HCA, Hypothermic circulatory arrest; CPB, cardio-
pulmonary bypass.
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